The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

The human immunodeficiency virus–type 1 (HIV-1) envelope glycoproteins interact with
receptors on the target cell and mediate virus entry by fusing the viral and cell membranes …

The Omicron variant continuously evolves under the humoral immune pressure exerted by
vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of a
complex of gp120 and gp41. gp120 determines viral tropism by binding to target-cell …

Established for 20 years as the definitive virology reference, the two-volume classic Fields
Virology is in its thoroughly revised, updated Fifth Edition. More than 100 world-renowned …

Virologic and immunologic studies were performed on five patients presenting with primary
human immunodeficiency virus type 1 (HIV-1) infection. CD8+ cytotoxic T lymphocyte (CTL) …

The current COVID-19 pandemic, caused by SARS-CoV-2, poses a serious public health
threat. Effective therapeutic and prophylactic treatments are urgently needed. Angiotensin …

The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency
virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines …

The lentivirus human immunodeficiency virus (HIV) causes AIDS by interacting with a large
number of different cells in the body and escaping the host immune response against it. HIV …

Infection with human immunodeficiency virus 1 (HIV-1) results in the dissemination of virus
to gut-associated lymphoid tissue. Subsequently, HIV-1 mediates massive depletion of gut …